Mabvax Therapeuticsnasdaqmbvxis A Clinical Stage Biotechnology Company With A Fully Human Antibody Discovery Platform Focused On The Rapid Translation Into Clinical Development Of Products To Address Unmet Medical Needs In The Treatment Of Cancerour Antibody Mvt 5873Is A Fully Human Igg1 Monoclonal Antibodymabthat Targets Sialyl Lewis Aslea An Epitope On Ca19 9And Is Currently In Phase 1 Clinical Trials As A Therapeutic Agent For Patients With Pancreatic Cancer And Other Ca19 9 Positive Tumorswith Our Collaborators Including Memorial Sloan Kettering Cancer Centerrockefeller Universitysarah Cannon Research Institutehonor Health And Imaging Endpointswe Have Treated 50 Patients With Either Our Therapeutic Antibody Designated As Mvt 5873 Or Our Pet Imaging Diagnostic Product Designated As Mvt 2163 In Phase 1 Clinical Studiesand Demonstrated Early Safetyspecificity For The Target And A Potential Efficacy Signalpatient Dosing Has Commenced For Our Lead Development Program In Phase 1 Clinical Study Of The Company S Radioimmunotherapy Product Mvt 1075
No conferences found for this company.
| Company Name | Mabvax Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
